ArticleEuropean journal of nuclear medicine and molecular imaging2009
Correlation of immunohistopathological expression of somatostatin receptor 2 with standardised uptake values in 68Ga-DOTATOC PET/CT.
Article in European journal of nuclear medicine and molecular imaging, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05278208 (Phase I/II Study of Lutathera in Patients With Recurrent and/or Progressive High-Grade Central Nervous System Tumors and Meningiomas That Demonstrate Uptake on DOTATATE PET), which is not on this map. Cited by 71 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Phase I/II Study of Lutathera in Patients With Recurrent and/or Progressive High-Grade Central Nervous System Tumors and Meningiomas That Demonstrate Uptake on DOTATATE PET
Who cites it
71 citing papers in PubMed, 1 synthesis or guideline pooled it, 162 citations in OpenAlex.
- In Vivo Versus In Vitro Somatostatin Receptor Expression in Neuroendocrine Neoplasms: A Systematic Review and Meta-Analysis of Correlation Studies.International journal of molecular sciences · 2025Pooled it
- Comparison ofEuropean journal of nuclear medicine and molecular imaging · 2020Trial
- Visualization of somatostatin receptors in prostate cancer and its bone metastases with Ga-68-DOTATOC PET/CT.Molecular imaging and biologyTrial
- Sclerosing epithelioid mesenchymal neoplasm of the pancreas: a rare mimicker of common pancreatic neoplasms.Hepatobiliary surgery and nutrition · 2026Article
- [European journal of nuclear medicine and molecular imaging · 2026Article
- Pathological validation ofScientific reports · 2025Article
- [Cancers · 2025Article
- Comparison ofRadiology. Imaging cancer · 2025Article
- Prediction of lesion-based response to PRRT using baseline somatostatin receptor PET.Frontiers in medicine · 2025Article
- Development of [European journal of nuclear medicine and molecular imaging · 2024Article
- Novel Detection of Pleomorphic Adenomas via Analysis ofCancers · 2024Article
- Gallium-68 labeled somatostatin receptor antagonist PET/CT in over 500 patients with neuroendocrine neoplasms: experience from a single center in China.European journal of nuclear medicine and molecular imaging · 2024Article
- Somatostatin receptor subtype expression and radiomics from DWI-MRI represent SUV of [68Ga]Ga-DOTATOC PET in patients with meningioma.Journal of neuro-oncology · 2023Article
- Somatostatin Receptor Targeted PET-CT and Its Role in the Management and Theranostics of Gastroenteropancreatic Neuroendocrine Neoplasms.Diagnostics (Basel, Switzerland) · 2023Review
- Standardized Uptake Values on SPECT/CT: A Promising Alternative Tool for Treatment Evaluation and Prognosis of Metastatic Neuroendocrine Tumours.Diagnostics (Basel, Switzerland) · 2023Article
- Correlation of somatostatin receptor PET/CT imaging features and immunohistochemistry in neuroendocrine tumors of the lung: a retrospective observational study.European journal of nuclear medicine and molecular imaging · 2022Observational
- Digital quantification of somatostatin receptor subtype 2a immunostaining: a validation study.European journal of endocrinology · 2022Article
- Frequency and Prognostic Significance of Intertumoural Heterogeneity in Multifocal Jejunoileal Neuroendocrine Tumours.Cancers · 2022Article
- Somatostatin receptor imaging with [European journal of nuclear medicine and molecular imaging · 2022Article
- Correlation of Somatostatin Receptor 2 Expression, 68Ga-DOTATATE PET Scan and Octreotide Treatment in Thymic Epithelial Tumors.Frontiers in oncology · 2022Article
11 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeIn clinical routine somatostatin analogue positron emission tomography/computed tomography (PET/CT) such as (68)Ga-DOTA-Tyr-octreotide (DOTATOC)-PET/CT could substitute conventional (111)In-Octreotide scintigraphy. Immunohistochemistry (IHC) for somatostatin receptor 2 (SSTR2) might be a tool to predict positivity of (68)Ga-DOTATOC in patients where initial staging was not performed, e.g., in incidental findings. We therefore compared a score of SSTR2-IHC with the in vivo standard uptake value (SUV) of preoperative or prebiopsy (68)Ga-DOTATOC PET/CT. MATERIALS AND
methodsIn 18 patients, (68)Ga-DOTATOC PET/CT scans were quantified with SUV calculations and correlated to a cell membrane-based SSTR2-IHC score (ranging from 0 to 3).
resultsNegative IHC scores were consistent with SUV values below 10. Furthermore, all score 2 and 3 specimens corresponded with high SUV values (above 15).
conclusionSSTR2-IHC scores correlated well with SUV values and we propose to use SSTR2 immunohistochemistry in patients missing a preoperative PET scan to indicate (68)Ga-DOTATOC-PET/CT as method for restaging and follow-up in individual patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.